Join the movement to end censorship by Big Tech. StopBitBurning.com needs donations and support.
DIRTY VAX AXED: FDA reverses endorsement of Moderna's new spike prion jab for Covid due to ZERO clinical recommendations for the "public at large"
By sdwells // 2025-06-09
Mastodon
    Parler
     Gab
 Copy
 
  • The FDA clarified its initial guidance on Moderna's updated COVID-19 vaccine – recommending it only for high-risk groups (ages 65+ and those 12–64 with underlying conditions), explicitly stating it does not endorse broader use due to insufficient evidence.
  • The agency is moving away from blanket recommendations, emphasizing individualized risk assessments and requiring stronger data (like placebo-controlled trials) for future approvals.
  • Moderna’s approval was based on a trial showing immune response "non-inferior" to its prior shot, but critics highlight the lack of placebo controls or real-world efficacy measurements (e.g., symptom reduction).
  • Moderna will conduct a placebo-controlled trial in healthy adults (50–64) to assess safety and effectiveness, with results expected by 2025.
  • The FDA’s cautious stance reflects a post-pandemic shift toward transparency and scientific rigor, balancing public health needs with waning public trust.
Finally, somebody somewhere is asking for clinical trials on the deadliest jabs ever created. The mRNA Covid stabs have caused more health detriment around the globe than every other vaccine ever invented and administered, combined. From healthy people having heart attacks and dying the same day as getting injected, to pregnant women having a spontaneous abortion right after vaccination, the horror story has just gone on and on, with ZERO checks and balances for what the Vaccine Industrial Complex calls “medicine.”

FDA clarifies limited endorsement of Moderna's updated COVID-19 vaccine amid scrutiny over data and lack thereof

The U.S. Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccine for select high-risk groups while explicitly distancing itself from broader recommendations, citing insufficient evidence for widespread use. The agency’s tempered stance reflects growing scrutiny over the scientific rigor behind vaccine approvals—a shift from its earlier pandemic-era posture. On May 31, the FDA authorized Moderna’s reformulated shot for individuals aged 65 and older, as well as those aged 12 to 64 with underlying health conditions like obesity or diabetes. But in a June 4 statement, Dr. Vinay Prasad, head of the FDA’s Center for Biologics Evaluation and Research, emphasized that approval does not equate to a clinical endorsement. “The FDA is not your doctor,” Prasad said in an agency video. “We are not in the business of making recommendations.” FDA Commissioner Dr. Marty Makary reinforced the message on social media, stating the agency’s role is “to review data and decide whether products are safe and effective.” The clarification comes as federal health officials pivot from blanket guidance toward individualized risk assessments. Prasad noted that future approvals for low-risk populations will require stronger evidence, including placebo-controlled trials measuring real-world outcomes like symptomatic illness reduction. The CDC has similarly scaled back its recommendations, retracting earlier advice that healthy children and pregnant women receive COVID-19 vaccines. The shift follows criticism that prior approvals relied on limited data—particularly for updated boosters targeting newer variants. Moderna’s latest authorization was based on a trial showing “non-inferior” immune responses compared to its previous shot, but the study lacked a placebo control group. To address gaps, Moderna will now conduct a placebo-controlled trial in healthy adults aged 50 to 64, using saline injections instead of an active comparator. “We’re going to see all the adverse events in this study,” Prasad said during a June 4 podcast. “We’re going to see whether or not it helps people… and whether or not it’s working like we think it might be in 2025.” The FDA’s recalibration marks a departure from its pandemic-era approach under former official Dr. Peter Marks, who frequently advocated for broad booster use. The agency now faces pressure to balance public health imperatives with demands for transparency—a tension heightened by evolving variants and waning public trust. As debates over vaccine policy persist, the FDA’s latest move underscores a broader reckoning with the limits of emergency-era decision-making. For now, the agency urges patients to consult physicians rather than rely on sweeping government guidance—a nuanced stance that may redefine post-pandemic health governance. The FDA’s cautious endorsement of Moderna’s updated vaccine signals a turning point in COVID-19 policy, prioritizing rigorous data over expedited approvals. While the shot remains an option for vulnerable groups, the agency’s reluctance to recommend it universally reflects lessons from the pandemic’s polarized landscape. As trials proceed, the balance between rapid response and scientific accountability will remain a critical test for public health institutions. Bookmark plague.info to your favorite independent websites for updates on new gain-of-function viruses the CDC and WHO release into the “wild” and then create deadly jabs to coincide with the fearmongering press campaign in fake news. Sources for this article include: Pandemic.news GatewayPundit.com NaturalNews.com Yournews.com
Mastodon
    Parler
     Gab
Copy